Sonoma Pharmaceuticals enters ATM equity offering agreement for up to $2.7M

Sonoma Pharmaceuticals, Inc.

ATM agreement with Ladenburg Thalmann to sell common stock up to $2,700,000 aggregate gross proceeds.
Ladenburg receives 3% commission on sales; Company reimburses up to $60,000 in expenses.
Sales conducted under existing effective S-3 shelf registration (filed Dec 22, 2020).
Company not obligated to sell any shares; agreement terminates upon completion or earlier per terms.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sonoma Pharmaceuticals, Inc. entered into At-The-Market Offering Agreement with Ladenburg Thalmann & Co. Inc. valued at aggregate offering price of up to $2,700,000 (effective 2022-12-23).

Action: entry
Agreement: atm program
Counterparty: Ladenburg Thalmann & Co. Inc.
Value: aggregate offering price of up to $2,700,000
Effective: 2022-12-23

Exact text from the filing

On December 23, 2022, we entered into an At-The-Market Offering Agreement, or the ATM Agreement, with Ladenburg Thalmann & Co. Inc. , as sales agent, pursuant to which we may offer and sell, from time to time, through Ladenburg shares of our common stock, $0.0001 par value per share.

View on SEC.gov

Browse all material agreements →

Sonoma Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-008632

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.